Diagnostic value of methylation for colorectal cancer: a meta-analysis.

As a common antagonist of Wnt/β-catenin signaling, Wnt inhibitory factor 1 () plays an important role in the tumor progression. The aim of our meta-analysis was to summarize the diagnostic value of methylation in colorectal cancer (CRC). Eligible studies were retrieved by a systemic search among PubMed, Embase, CNKI, and Wanfang literature databases. The diagnostic value of methylation for CRC was assessed by the summary receiver operating characteristics (SROC) test. Our meta-analysis of 12 studies between 1420 CRC samples and 946 control samples showed that hypermethylation was significantly associated with CRC ( < 0.001, OR = 30.10, 95% CI = 19.48-46.50). hypermethylation, as a diagnostic biomarker for CRC, has a pooled sensitivity of 0.40 (95% CI: 0.37-0.42), a pooled specificity of 0.95 (95% CI: 0.93-0.96), a pooled positive-likelihood ratio (PLR) of 8.65 (95% CI, 4.47-16.73), and a pooled negative-likelihood ratio (NLR) of 0.41 (95% CI, 0.30-0.55), a diagnostic odds ratio (DOR) of 26.86 (95% CI: 15.73-45.89), and an area under the curve (AUC) of 0.9115. In conclusion, our study established that hypermethylation might be a promising diagnostic biomarker for CRC.